PROM1 and glioblastoma: Although expression of CD133 is associated with poor clinical outcomes in GBM patients and PROM1 expression is required for defining stem cells giving rise to cancer, there are additional markers as well that are identified for different cellular features including cellular characteristics, origins and hierarchy.